Clinical trials: Head Neck Neoplasms
Solid Tumor
Study in Advanced Solid Tumors
The primary purpose of this study is to help answer the following research question(s): To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with cisplatin [pharmacokinetic (PK)…
- Trial name
- NCT01099358
- Testing
- Cetuximab, Cisplatin, 5 - Fluorouracil
- Where
- 7 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Head and Neck Cancer
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck
This pilot study is designed to evaluate the feasibility of delivering ultra-high dose-rate conformal proton therapy (ConformalFLASH) in participants requiring re-irradiation for head and neck cancer who are not amenable to…
- Trial name
- C-FLASH-01 (NCT07644585)
- Testing
- ConformalFLASH irradiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- IBA Proton Therapy, Inc.
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed…
- Trial name
- NCT03933449
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Where
- 23 sites in China
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Thoracic Cancer, Pancreatic Cancer Non-resectable
Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System
This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent…
- Conditions
- Thoracic Cancer, Pancreatic Cancer Non-resectable, Brain Cancer, Head Cancer
- Trial name
- PPTS (NCT05549414)
- Testing
- Proton Radiation
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- P-Cure
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
Barrett's Esophagus, Esophageal Cancer
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.
- Trial name
- NCT01293448
- Testing
- Cryoballoon Ablation
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 21 people
- Sponsor
- Pentax Medical
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic…
- Conditions
- Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Trial name
- NCT06782555
- Testing
- Evofosfamide, Zalifrelimab, Balstilimab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- ImmunoGenesis
Radiation Induced Mucositis in Head and Neck Cancer
A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00
A Clinical Study to Assess Radiation Induced Mucositis in Subjects with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT01903018
- Testing
- P276-00, Radiation Therapy, Cisplatin
- Where
- 7 sites in India
- Volunteers
- 73 people
- Sponsor
- Piramal Enterprises Limited
Head and Neck Neoplasm, Prostatic Neoplasm
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET] scans due to advanced non-hematologic…
- Conditions
- Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm
- Trial name
- NCT00666926
- Testing
- PF00562271
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 99 people
- Sponsor
- Verastem, Inc.
Nasopharyngeal Carcinoma
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.
- Trial name
- NCT04895345
- Testing
- TQB2450, Intensity modulated radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Melanoma, Squamous Cell Carcinoma of Head and Neck
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment.
- Trial name
- NCT05280314
- Testing
- IO102-IO103, Pembrolizumab KEYTRUDA®
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- IO Biotech
Squamous Cell Carcinoma of the Head and Neck
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among…
- Trial name
- VOLUME-PRO (NCT05068609)
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 509 people
- Sponsor
- Bristol-Myers Squibb
Barrett Esophagus, Esophageal Cancer
Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus
Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different…
- Trial name
- NCT05846971
- Testing
- Educational materials on validated methylation assay
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Capsulomics, Inc.
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Oral Neoplasm
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral…
- Trial name
- NCT04622462
- Testing
- Standard of Care Histopathology, STRATICYTE Assessment
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- Proteocyte Diagnostics Inc.
Squamous Cell Carcinoma
Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device.
- Trial name
- DaRT (NCT03015883)
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Alpha Tau Medical LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.